{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:08:20Z","timestamp":1779113300698,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373874"],"award-info":[{"award-number":["82373874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173825"],"award-info":[{"award-number":["82173825"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bcp.2026.117810","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:04:44Z","timestamp":1770998684000},"page":"117810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis"],"prefix":"10.1016","volume":"247","author":[{"given":"Qinghe","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117810_b0005","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.117810_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2016.09.017","article-title":"Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence","volume":"30","author":"Awolaran","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2026.117810_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2022.03.008","article-title":"Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications","volume":"86","author":"Mehraj","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.117810_b0020","article-title":"Unusual gastric metastasis in triple-negative (estrogen receptor\/progesterone receptor\/HER2neu negative) GATA-binding protein 3-positive breast cancer","volume":"35","author":"Baa","year":"2020","journal-title":"Indian Journal of Nuclear Medicine"},{"key":"10.1016\/j.bcp.2026.117810_b0025","doi-asserted-by":"crossref","unstructured":"C.E. DeSantis, J. Ma, M.M. Gaudet, L.A. Newman, K.D. Miller, A. Goding Sauer, A. Jemal, R.L. Siegel, Breast cancer statistics, 2019, CA Cancer J. Clin. 69 (2019). doi:10.3322\/caac.21583.","DOI":"10.3322\/caac.21583"},{"key":"10.1016\/j.bcp.2026.117810_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6311-z","article-title":"The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.117810_b0035","doi-asserted-by":"crossref","DOI":"10.3325\/cmj.2021.62.270","article-title":"The pathogenesis of bone metastasis in solid tumors: A review","volume":"62","author":"Vi\u010di\u0107","year":"2021","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.bcp.2026.117810_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107903","article-title":"Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases","author":"Zou","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117810_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.117810_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2015.11.017","article-title":"Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer","volume":"99","author":"Futakuchi","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2026.117810_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.117810_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2026.117810_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1594-1","article-title":"IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis","volume":"10","author":"Liang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.117810_b0070","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-05-2630","article-title":"Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-\u03baB ligand pathway","volume":"65","author":"Bendre","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117810_b0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"Biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117810_b0080","article-title":"X. yuan Liu, AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis","volume":"435","author":"C. hong Li, J. xia Zhao, L. Sun, Z. qiang Yao, X. li Deng, R. Liu,","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.117810_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2026.117810_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-\u03baB and the link between inflammation and cancer","volume":"246","author":"Didonato","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2026.117810_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.117810_b0100","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117810_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020395","article-title":"Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells","volume":"18","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117810_b0110","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-23-0383","article-title":"SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment","volume":"13","author":"Sodir","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117810_b0115","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy?","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117810_b0120","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"Shp2 inhibition prevents adaptive resistance to mek inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.117810_b0125","article-title":"SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion","volume":"29","author":"Zhou","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.117810_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/nature12396","article-title":"Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling","volume":"499","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117810_b0135","article-title":"From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis","volume":"1","author":"Yang","year":"2013","journal-title":"Rare Dis."},{"key":"10.1016\/j.bcp.2026.117810_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37593-8","article-title":"Mapping the landscape of genetic dependencies in chordoma","volume":"14","author":"Sharifnia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117810_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110316","article-title":"Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos\/NFATc1 signaling","volume":"120","author":"Yang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.117810_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01527-y","article-title":"DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117810_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153377","article-title":"Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways","volume":"80","author":"Zou","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.117810_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.02.015","article-title":"Sinomenine inhibits osteolysis in breast cancer by reducing IL-8\/CXCR1 and c-Fos\/NFATc1 signaling","volume":"142","author":"Zhang","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117810_b0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jare.2024.03.021","article-title":"Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction","volume":"69","author":"Zheng","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bcp.2026.117810_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-019-1220-2","article-title":"Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts","volume":"21","author":"Lefley","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.117810_b0175","article-title":"Punicalin Attenuates Breast Cancer-Associated Osteolysis by Inhibiting the NF-\u03baB Signaling Pathway of Osteoclasts","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117810_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115704","article-title":"Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway","volume":"215","author":"Mao","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117810_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2005.12.018","article-title":"1\u03b1,25(OH)2-Vitamin D3 stimulates intestinal cell p38 MAPK activity and increases c-Fos expression","volume":"38","author":"Pardo","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2026.117810_b0190","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-12-196535","article-title":"Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera","volume":"115","author":"Randi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.117810_b0195","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M113.504639","article-title":"Inside-out signaling promotes dynamic changes in the carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) oligomeric state to control its cell adhesion properties","volume":"288","author":"Patel","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.117810_b0200","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14335","article-title":"Platelet Shp2 negatively regulates thrombus stability under high shear stress","volume":"17","author":"Hu","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.117810_b0205","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0510876103","article-title":"Gain-of-function\/Noonan syndrome SHP-2\/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling","volume":"103","author":"Uhl\u00e9n","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.117810_b0210","doi-asserted-by":"crossref","DOI":"10.7150\/thno.58468","article-title":"Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition","volume":"11","author":"Yuan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.117810_b0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1757-7861.2010.00095.x","article-title":"Chinese Orthopaedic Association Bone Oncology Group, Experts\u2019 agreement on therapy for bone metastases","volume":"2","author":"Du","year":"2010","journal-title":"Orthop. Surg."},{"key":"10.1016\/j.bcp.2026.117810_b0220","doi-asserted-by":"crossref","DOI":"10.1038\/nrendo.2015.185","article-title":"The best of both worlds-managing the cancer, saving the bone","volume":"12","author":"Makhoul","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2026.117810_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117810_b0230","article-title":"NCCN task force report: Bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"10.1016\/j.bcp.2026.117810_b0235","article-title":"RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis","volume":"68","author":"O\u2019Brien","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1016\/j.bcp.2026.117810_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-3835(01)00524-9","article-title":"Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases","volume":"169","author":"Sotiriou","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.117810_b0245","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10555-024-10211-9","article-title":"The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy","volume":"43","author":"Chen","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2026.117810_b0250","doi-asserted-by":"crossref","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancermetastasis through RANKL-RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117810_b0255","article-title":"A ERK\/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K\/AKT activation in macrophages","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.117810_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116391","article-title":"A p38 MAP kinase inhibitor suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss through the inhibition of bone turnover","volume":"226","author":"Xu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117810_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.03.034","article-title":"Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis","volume":"42","author":"Heun","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.117810_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169311","article-title":"Ciliary Neurotrophic Factor (CNTF) Inhibits In Vitro Cementoblast Mineralization and Induces Autophagy, in Part by STAT3\/ERK Commitment","volume":"23","author":"Yong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117810_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110034","article-title":"Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f\/SHP1\/SHP2 phosphorylation","volume":"118","author":"Dang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.117810_b0280","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-024-01157-7","article-title":"Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases","volume":"56","author":"Takegahara","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2026.117810_b0285","doi-asserted-by":"crossref","DOI":"10.2183\/pjab.83.136","article-title":"Interaction between the immune system and bone metabolism: An emerging field of osteoimmunology","volume":"83","author":"Takayanagi","year":"2007","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.117810_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-022-00219-8","article-title":"Bone remodeling: an operational process ensuring survival and bone mechanical competence","volume":"10","author":"Bolamperti","year":"2022","journal-title":"Bone Res."},{"key":"10.1016\/j.bcp.2026.117810_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155688","article-title":"Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor","volume":"129","author":"Chen","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.117810_b0300","doi-asserted-by":"crossref","DOI":"10.1007\/s00256-023-04326-3","article-title":"Computed tomography density changes of bone metastases after concomitant denosumab","volume":"52","author":"Mallio","year":"2023","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.bcp.2026.117810_b0305","doi-asserted-by":"crossref","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117810_b0310","doi-asserted-by":"crossref","DOI":"10.1007\/s10753-023-01784-8","article-title":"Inhibition of SHP2 by the Small Molecule Drug SHP099 Prevents Lipopolysaccharide-Induced Acute Lung Injury in Mice","volume":"46","author":"Ye","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.bcp.2026.117810_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117810_b0320","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-022-00618-w","article-title":"Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders","volume":"22","author":"Stanford","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.117810_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2015.03.027","article-title":"Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases","volume":"23","author":"Chio","year":"2015","journal-title":"Bioorg. Med. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:09:36Z","timestamp":1779109776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"alternative-id":["S0006295226001413"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117810","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117810"}}